ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program

Our Future Health’s trusted research environment will collect information from millions of volunteers and provide tools to transform the prevention, detection, and treatment of diseases

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that it has been awarded a three-year contract by Our Future Health. The DNAnexus platform, which will be hosted in the UK, will provide approved researchers with a scalable, cloud-based trusted research environment for accessing and analyzing Our Future Health’s growing biomedical dataset and tools to drive biological insights and global collaborations to advance precision medicine.

Our Future Health is an ambitious collaboration among the public, private, and non-profit sectors designed to help scientists develop new ways to prevent, detect, and treat disease. The program aims to recruit up to 5 million adult volunteers, which is more than 9% of the adult population in the UK. Approved researchers from the global life sciences, healthcare, and academic communities will be able to use the DNAnexus platform to securely explore and analyze the de-identified data.

Andrew Roddam, CEO of Our Future Health, said: “We’re delighted that DNAnexus will be delivering our trusted research environment. It’s an incredibly important decision because providing an environment for researchers to work with participants’ data in a safe, secure, and controlled way is a top priority for Our Future Health. DNAnexus will be a really important partner as we work towards achieving our goal to help researchers develop new ways to prevent, detect, and treat diseases.”

Today, DNAnexus has more than 12,000 platform users across 48 countries and counts seven of the top 10 pharmaceutical and eight of the top 10 diagnostic companies as customers. The company built and continues to support the Research Analysis Platform for the UK Biobank, another large-scale biomedical resource that contains in-depth genetic and health information from half a million UK participants. The protected cloud environment was designed to meet the most rigorous standards for data quality, scalability, security, privacy, and safety.

“Our Future Health will be a huge step forward for genomic-based science in the UK and around the world. We are very excited that this ambitious health research program, the largest of its kind, will utilize the power of our industry-leading biomedical data analysis platform and expertise,” said Richard Daly, CEO at DNAnexus. “Together with Our Future Health and the UK Biobank, we are proud to be the partner of choice for transformative population research programs, and we look forward to empowering more researchers to accelerate the era of precision medicine.”

About Our Future Health

Our Future Health is a collaboration between the public, private and charity sectors. It aims to be the UK’s largest health research programme, bringing people together to develop new ways to prevent, detect and treat disease.

Our Future Health is committed to the highest standards, policies and processes that protect participants’ confidentiality, whilst maximising the opportunity to help researchers to tackle serious diseases. Participants’ data will be de-identified and held securely in trusted research environments that meet strict security criteria. There will be a robust and transparent access process to ensure appropriate research access to Our Future Health data and samples for registered researchers. All researchers – whether employed by universities, government, the NHS, charities or companies – will be held to the same standards.

Our Future Health is a member of the UK Health Data Research Alliance, the independent alliance of leading healthcare and research organisations establishing best practice for the ethical use of UK health data for research at scale.

Our Future Health is a company limited by guarantee registered in England and Wales (number 12212468) and a charity registered with the Charity Commission for England and Wales (charity number 1189681) and OSCR, Scottish Charity Regulator (charity number SC050917).

Learn more at www.ourfuturehealth.org.uk.

About DNAnexus

To improve human health, researchers and clinicians need to access complex and sensitive biomedical data and innovative technologies that can enable novel insights. However, these data are often incompatible or difficult to process. DNAnexus is the leading bioinformatics company that facilitates secure access and utilization of biomedical data while supporting collaboration across internal and external teams. The end-to-end integrated diagnostic R&D and production bioinformatics platform enables national biobank biomedical initiatives to provide pharmaceutical companies with a multi-omics data science platform for new target drug discovery, DNAnexus empowers the healthcare and life sciences industry to transform how they leverage biomedical data to accelerate scientific discoveries and deliver better patient care. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.